Phase II Clinical Study of BTDS in Japanese Patients with Cancer Pain

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223363

Enrollment

Registered

2016-11-02

Start date

2016-10-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer pain

Interventions

investigational material(s) Generic name etc : BTDS INN of investigational material : Buprenorphine Therapeutic category code : 114 Antipyretics, analgesics and anti-inflammatory agents Dosage and Adm

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with cancer

Exclusion criteria

Exclusion criteria: - Patients whom the investigator/subinvestigator judges might not be appropriate for the study due to skin sensitivity, etc. at the application site - Patients with severe respiratory depression or respiratory dysfunction

Design outcomes

Primary

Measure	Time frame
efficacy Pain control achievement rate	—

Secondary

Measure	Time frame
safety Safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026